INTERVIEW: Proteome Sciences advances targeted pancreatic cancer approach
This article was originally published in Clinica
Executive Summary
UK firm Proteome Sciences is hoping to take targeted medicine to a new level. The firm is developing technology to help identify which patients – potentially with any disease – will respond to certain drugs that could be just two years away from the clinic.